HealthyHealthy volunteersDrugPhase 1
What this study is
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
What's being tested
- NSHO-101
Intervention · DRUG
Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days
Study details
- Official title
- A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
- Sponsor
- Ensho Therapeutics, Inc.
- Conditions
- Healthy
- Enrolling
- 24 people
- Starts
- 2026-01-31
- Est. completion
- 2026-06
- Design
- Double-blind, randomized, parallel groups, Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Participants (males and females) at least 18 years of age
- Ability to provide written informed consent
- In good heath as determined by medical evaluation,
- Willing and able to comply with trial restrictions, procedures, and requirements
You can't join if
- Known sensitivity to any components of the IMP
- History of relevant drug hypersensitivity
- Presents or has a history of clinically significant diseases
- History of difficulty swallowing tablets or capsules.
- Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openCenexel Anaheim CA
Anaheim, California, United States
Recruiting
Study team
Sponsor
Ensho Therapeutics, Inc.
Study ID NSHO-101-HV202
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.